| Project/Area Number |
12672235
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
応用薬理学・医療系薬学
|
|---|
| Research Institution | Daiichi College of Pharmaceutical Sciences |
|---|
Principal Investigator |
SAKURADA Tsukasa Daiichi College of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, professor, 薬学部, 教授 (80124907)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKURADA Chikai Daiichi College of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, associate professor, 薬学部, 助教授 (30279244)
|
|---|
| Project Period (FY) |
2000 – 2002
|
| Project Status |
Completed (Fiscal Year 2002)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2002: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2001: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2000: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | substance P / intrathecal injection / pain-related behavior / NK_1 receptor antagonist / opioid action / NK_1受容体 / オビオイド受容体 / サブスタンスPアナログ / マウス脊髄シナプス膜標本 / ナロキソン |
|---|
| Research Abstract |
1) Effects of sendide and [D-Arg^2]sendide on pain-related behavior induced by substance P (SP)
Sendide, given simultaneously with SP, reduced the SP-induced behavioral response with an ID_<50> of 0.3 pmol. [D-Arg^2]sendide co-injected with SP produced a dose dependent reduction with an ID_<50> of 115.5 fmol.
2) Duration of antagonistic action of sendide and [D-Arg^2]sendide
The antagonistic action of sendide on SP-induced behavior at doses of 4.0 and 8.0 nmol lasted for 120 and 180 min, respectively. The duration of the antagonistic effect of [D-Arg^2]sendide at doses of 0.5 and 4.0 pmol was 60 and 120 min, respectively.
3) Effects of naloxone pretreatment on the inhibitory action of sendide and [D-Arg^2]sendide
Naloxone (0.5 - 4.0 mg/kg) pretreatment gave no significant antagonism against sendide. The inhibitory action of [D-Arg^2]sendide on SP-induced behavior was antagonized by naloxone (4.0 mg/kg), but not by lower doses of naloxone (1.0 and 2.0 mg/kg).
4) Binding properties of sendide for NK_1 receptors
Sendide displaced the binding of [^3H]-SP to mouse spinal cord membranes. The Ki for unlabeled SP and sendide was 3.3 ± 0.7 and 4.0 ± 1.0 pM, respectively, indicating that sendide was approximately 800 times more potent than SP.
5) Binding properties of sendide for mu and delta opioid receptors
Sendide displaced the binding of [^3H]-DAMGO to mouse spinal cord membranes. On the basis of Ki values sendide was approximately 100 times as weak as unlabeled binding sites. Sendide had a lower affinity for [^3H]-deltorphin binding sites.
These results suggest that sendide and [D-Arg^2]sendide at lower doses may be a relatively selective action at the tachykinin NK_1 receptors in the spinal cord, and at higher doses these antagonists may possess opioid activities in addition to an antagonistic action at NK_1 receptors.
|
